IDiyas

For the Inventor, By the Inventor

Cambridge, United Kingdom

Lutz Jermutus

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 36(Granted Patents)


Company Filing History:

goldMedal13 out of 541 
 
Medimmune Limited
 patents

Years Active: 2010-2024

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 12076406 - Conjugates for targeting and clearing aggregates (2024-09-03),
2. 11525012 - Binding molecules specific for CD73 and uses thereof (2022-12-13),
3. 11065336 - Conjugates for targeting and clearing aggregates (2021-07-20),
4. 10676517 - Glucagon and GLP-1 co-agonists for the treatment of obesity (2020-06-09),
5. 10556968 - Binding molecules specific for CD73 and uses thereof (2020-02-11),
6. 10287362 - Binding molecules specific for CD73 and uses thereof (2019-05-14),
7. 10184008 - Blood brain barrier transport molecules and uses thereof (2019-01-22),
8. 9938356 - Binding molecules specific for CD73 and uses thereof (2018-04-10),
9. 9856317 - Human antibody molecules for IL-13 (2018-01-02),
10. 9315575 - Methods of treatment using human antibody molecules for IL-13 (2016-04-19),
11. 8288123 - Methods and means relating to protein variants (2012-10-16),
12. 7947273 - Human antibody molecules for IL-13 (2011-05-24),
13. 7829090 - Human antibody molecules for IL-13 (2010-11-09),

Title: Lutz Jermutus: Innovator in Biopharmaceuticals

Introduction

Lutz Jermutus is a prominent inventor based in Cambridge, GB, known for his significant contributions to the field of biopharmaceuticals. With a total of 13 patents to his name, he has made remarkable advancements in therapeutic technologies aimed at treating various diseases.

Latest Patents

Among his latest patents is a conjugate designed for targeting and clearing aggregates. This invention includes a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor, along with a targeting moiety that specifically targets molecular aggregates. Additionally, he has developed binding molecules specific for CD73, which include antibodies and their antigen-binding fragments. These innovations are crucial for diagnosing and treating diseases associated with CD73 expression, such as cancer. His methods encompass direct therapy with anti-CD73 binding molecules, adjuvant therapy with other anticancer agents, and combination therapies with chemotherapy.

Career Highlights

Lutz Jermutus has worked with notable companies in the biopharmaceutical sector, including Medimmune Limited and Cambridge Antibody Technology Limited. His work has significantly impacted the development of therapeutic solutions in the industry.

Collaborations

He has collaborated with esteemed colleagues such as Ralph Raymond Minter and Carl Hay, contributing to the advancement of innovative biopharmaceutical technologies.

Conclusion

Lutz Jermutus stands out as a key figure in the field of biopharmaceuticals, with a strong portfolio of patents and collaborations that highlight his innovative spirit. His work continues to influence the development of therapies for complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…